Retrospective analysis indicates treatment success varies between drug-sensitive TB and MDR-TB patients.
Background: Tuberculosis (TB) continues to be a major health problem in India. Multi-drug resistant TB (MDR-TB) creates significant challenges for treatment. Methods: A retrospective study took place at Government Medical College Hospital in the Southern Coastal Region of Tamil Nadu. It involved 350 patients (250 with pulmonary TB and extra-pulmonary TB, and 100 with MDR-TB) between 2023 and 2024. We analyzed data on demographics, risk factors, treatment plans, and outcomes. Results: Among the 350 patients, 60% were male, most aged 21 to 40 years. Pulmonary TB made up 65% of cases, extra-pulmonary TB 35%, and MDR-TB accounted for 28.6%. Common risk factors included malnutrition, smoking, HIV, and diabetes. The success rate for treatment was 78% for drug-sensitive TB and 62% for MDR-TB, with higher mortality in MDR-TB cases. Conclusion: Standard treatment plans are effective for pulmonary and extra-pulmonary TB, but the results for MDR-TB are still poor. Early drug sensitivity testing, better adherence to treatment, and access to newer regimens are essential for improving outcomes.
No takes yet. Share an insight, caveat, or question.
Selvamuthu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: